We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More XPhase 1 trial evaluating the safety and clinical activity of CYAD-02 is planned for early 2020 and will involve a preconditioning chemotherapy in patients with relapse/refractory acute myeloid leukemia or myelodysplastic syndromes (Credit: Wikimedia Commons)